InsiderPulse
Dashboard

ACAD

ACADIA Pharmaceuticals Inc.

Health CareRussell 2000

ACADIA Pharmaceuticals Inc. insider trading

ACADIA Pharmaceuticals Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in San Diego, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent ACAD insider transactions

5 insiders traded ACAD on the open market between Mar 25, 2026 and Aug 06, 2026 — 20 sales worth $2.2M, of which 4 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$2.2M

4 of 20 on a 10b5-1 plan

Net
−$2.2M
Insiders
5

Open-market purchases (code P) and sales (code S) from ACADIA Pharmaceuticals Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every ACAD Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

ACAD insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 10 insiders traded ACAD on the open market: 0 purchases and 41 sales worth $5M, 5 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 22 sales ($3.1M), by 7 insiders.

QuarterBoughtSold
Q2 2026—−$600.7K6 sales · 1 on a plan
Q1 2026—−$769.7K10 sales
Q4 2025—−$1M3 sales
Q3 2025—−$678.3K3 sales · 1 on a plan
Q2 2025—−$580.4K8 sales · 3 on a plan
Q1 2025—−$187.3K5 sales
Q4 2024—−$414.6K3 sales
Q3 2024—−$779.5K3 sales
Largest sale
−$671.1K of ACAD by Daly James M (Director) on Nov 10, 2025.

Open-market transactions through Jun 30, 2026most recent first

  • Kihara James10b5-1

    Principal Accounting Officer

    −$297.9K

    Jun 26, 2026

    11,421 sh · $26.08

  • Rhodes Jennifer J

    EVP, Chief Legal Officer, Sec

    −$162.5K

    Feb 09, 2026

    6,950 sh · $23.38

  • Schneyer Mark C.

    EVP, Chief Financial Officer

    −$243.1K

    Nov 18, 2025

    10,262 sh · $23.69

  • Kihara James

    Principal Accounting Officer

    −$96.8K

    Nov 18, 2025

    4,084 sh · $23.69

  • Daly James M

    Director

    −$671.1K

    Nov 10, 2025

    30,000 sh · $22.37

  • Schneyer Mark C.

    EVP, Chief Financial Officer

    −$82.7K

    Sep 15, 2025

    3,498 sh · $23.65

  • Garofalo Elizabeth A.

    Director

    −$41.6K

    Sep 02, 2025

    1,600 sh · $25.98

  • Schneyer Mark C.10b5-1

    EVP, Chief Financial Officer

    −$554K

    Aug 18, 2025

    22,000 sh · $25.18

  • Brege Laura

    Director

    −$314.6K

    Jun 04, 2025

    14,446 sh · $21.78

  • Kihara James10b5-1

    Principal Accounting Officer

    −$50K

    May 16, 2025

    2,000 sh · $25.00

  • Schneyer Mark C.10b5-1

    EVP, Chief Financial Officer

    −$50K

    May 16, 2025

    2,000 sh · $25.00

  • Kihara James10b5-1

    Principal Accounting Officer

    −$40K

    May 16, 2025

    2,000 sh · $20.00

  • Schneyer Mark C.

    EVP, Chief Financial Officer

    −$51.1K

    May 02, 2025

    3,498 sh · $14.60

  • Kihara James

    Principal Accounting Officer

    −$19.4K

    May 02, 2025

    1,327 sh · $14.60

  • Schneyer Mark C.

    EVP, Chief Financial Officer

    −$40.1K

    Apr 08, 2025

    2,708 sh · $14.82

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

ACADIA Pharmaceuticals Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
San Diego, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001070494

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought ACAD

What the stock actually did in the 90 days following each open-market purchase

Don't check ACAD — let it ping you

Get told the moment an insider moves on ACAD

Pro watches ACADIA Pharmaceuticals Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add ACAD to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track ACAD on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read ACAD insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

PTCTMEDPDNLIVEEVTEMALKSAPLSARVNBBIOCYTKDAWNDYN
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are ACAD insiders buying or selling?
Between Mar 25, 2026 and Aug 06, 2026, 5 ACADIA Pharmaceuticals Inc. insiders made no open-market purchases and 20 sales worth $2.2M, a net sale of $2.2M. 4 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much ACAD stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 10 ACADIA Pharmaceuticals Inc. insiders made no open-market purchases and 41 sales worth $5M. 5 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 22 sales ($3.1M). The largest sale was Daly James M selling $671.1K on Nov 10, 2025.
What was the largest recent ACAD insider trade?
Thompson Elizabeth H.Z. (EVP, Head of Research & Dev) sold $431.4K of ACAD stock on Jul 30, 2026 at about $26.13 a share.
When did an insider last buy ACAD shares?
No open-market purchase by a ACADIA Pharmaceuticals Inc. insider appears in the filings from Mar 25, 2026 to Aug 06, 2026 — every recorded open-market transaction in that period was a sale.
Where does ACAD insider trading data come from?
From the Form 4 filings ACADIA Pharmaceuticals Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.